Theranostics 13 , 50755098 (2023)
The core threat is disintermediation, where patients get a one-time prescription from their primary care doctor and then access GLP-1s directly through TrumpRx rather than paying $145/month for Ro's subscription that bundles telehealth, labs, titration, and coaching, forcing Ro to immediately cut Wegovy prices to $349/month to match TrumpRx's floor and raising the strategic question of whether Ro's care management can justify a subscription when patients can route around it
doi: 10.5585/conssaude.v9i4.2307 215 YoshikawaMMurakamiTKadoyaMMatsudaHMuraokaOYamaharaJet al
Whilst there is no specific contraindication against concurrent use, combining these medications requires careful medical assessment
Many people will not experience side effects with oral Semaglutide
Disconnected systems and unreliable data dont just slow manufacturers down - they quietly erode margins, increase risk, and limit growth